Guggenheim raised the firm’s price target on ANI Pharmaceuticals to $77 from $70 and keeps a Buy rating on the shares after the company “once again” delivered record quarterly cortrophin gel net revenues “well above” the firm’s recently increased expectations. In addition, the company’s s initial FY24 guidance “appears reasonable and encouraging to us, with plenty of room for upside,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $83 from $73 at H.C. Wainwright
- ANI Pharmaceuticals price target raised to $80 from $72 at Truist
- ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
- ANI Pharmaceuticals sees FY24 adjusted EPS $4.26-$4.67, consensus $4.33
- ANI Pharmaceuticals reports Q4 adjusted EPS $1.00, consensus 85c
